Compare · DFTX vs MTEX
DFTX vs MTEX
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Mannatech Incorporated (MTEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MTEX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.39B, about 361.1x MTEX ($12.2M).
- Over the past year, DFTX is up 183.5% and MTEX is down 11.7% - DFTX leads by 195.2 points.
- DFTX has been more active in the news (10 items in the past 4 weeks vs 3 for MTEX).
- DFTX has more recent analyst coverage (8 ratings vs 0 for MTEX).
PerformanceDFTX+183.48%MTEX-11.73%
2025-11-17+0.00%2026-11-13
- Company
- Definium Therapeutics Inc.
- Mannatech Incorporated
- Price
- -
- -
- Market cap
- $4.39B
- $12.2M
- 1M return
- -6.32%
- +10.39%
- 1Y return
- +183.48%
- -11.73%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 10
- 3
- Recent ratings
- 8
- 0
MTEX
Mannatech Incorporated
Mannatech, Incorporated operates as a health and wellness company worldwide. It develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management products. The company primarily sells its products directly, as well as through network marketing channels and a website. Mannatech, Incorporated was founded in 1993 and is headquartered in Flower Mound, Texas.
Latest DFTX
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics to Participate at Upcoming Investor Conferences
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
- Definium Therapeutics Announces New Employee Inducement Grants
Latest MTEX
- Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mannatech Incorporated
- Mannatech Reports Financial Results for Third Quarter 2026
- Amendment: SEC Form 8-K/A filed by Mannatech Incorporated
- SEC Form 8-K filed by Mannatech Incorporated
- SEC Form 8-K filed by Mannatech Incorporated
- Mannatech Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Mannatech Announces Retirement of J. Stanley Fredrick from the Board and Appointment of Robert Toth as Chairman of the Board
- Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mannatech Incorporated